Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
2003 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

2 results

Results by year

Filters applied: . Clear all
Page 1
Clinical effects of gonadotropin-releasing hormone analogue in metastatic carcinoma of prostate.
Smith JA Jr, Glode LM, Wettlaufer JN, Stein BS, Glass AG, Max DT, Anbar D, Jagst CL, Murphy GP. Smith JA Jr, et al. Among authors: anbar d. Urology. 1985 Feb;25(2):106-14. doi: 10.1016/0090-4295(85)90523-0. Urology. 1985. PMID: 3918369 Clinical Trial.
Considering the lack of significant side effects seen with long-term GnRH agonists, compounds such as leuprolide may prove to be the preferred initial endocrine therapy for selected patients with metastatic carcinoma of the prostate....
Considering the lack of significant side effects seen with long-term GnRH agonists, compounds such as leuprolide may prove to be the …
A model for the interim analysis process: a case study.
Delgado-Herrera L, Anbar D. Delgado-Herrera L, et al. Among authors: anbar d. Control Clin Trials. 2003 Feb;24(1):51-65. doi: 10.1016/s0197-2456(02)00275-1. Control Clin Trials. 2003. PMID: 12559642
The pivotal phase II/III trial for the new drug application was very expensive, large, long term, and slow-accruing. The trial was initiated with a great deal of uncertainty concerning the safety and efficacy of the proposed treatment. ...
The pivotal phase II/III trial for the new drug application was very expensive, large, long term, and slow-accruing. The trial was in …